Goldman Sachs has kept a sell rating on Sun Pharma but has increased the target price to Rs 1,450 from Rs 1,350.
While growth in India appears strong, it conceals a slowdown in specialty segments. Valuations do not reflect various risks, including the ongoing global specialty market slowdown, softening growth in India, and sluggish performance in the US generic business.
Comments
Post a Comment